首页> 外文OA文献 >Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial

【2h】

Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial

机译：患者和医生报告的症状不良事件结果的分歧是用一线加妥昔单抗和化疗治疗不可切种的转移性结直肠癌的患者的预后差：II期嘎嘎试验的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Akira Ooki; Satoshi Morita; Akihito Tsuji; Shigeyoshi Iwamoto; Hiroki Hara; Hiroaki Tanioka; Hironaga Satake; Masato Kataoka; Masahito Kotaka; Yoshinori Kagawa; Masato Nakamura; Tatsushi Shingai; Masashi Ishikawa; Yasuhiro Miyake; Takeshi Suto; Yojiro Hashiguchi; Taichi Yabuno; Masahiko Ando; Junichi Sakamoto; Kensei Yamaguchi;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial [J] . Shigeyoshi Iwamoto, Akira Ooki, Satoshi Morita, Cancer Medicine . 2018,第9期

机译：一项前瞻性II期研究旨在检查KRAS野生型不可切除转移性结直肠癌患者的生活质量与一线化疗加西妥昔单抗不良事件之间的关系：QUACK试验
2. Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial [J] . Akira Ooki, Satoshi Morita, Shigeyoshi Iwamoto, Cancer Medicine . 2020,第5期

机译：患者报告的症状负担作为用第一线Cetuximab加上化疗进行治疗的预后因素，用于不可切种的转移性结直肠癌：II期嘎嘎试验的结果
3. A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial [J] . OokiA., AndoM., SakamotoJ., Japanese journal of clinical oncology. . 2014,第4期

机译：一项前瞻性观察性研究，以探讨KRAS野生型不可切除转移性结直肠癌患者一线化疗加西妥昔单抗的生活质量与不良事件之间的关系：QUACK试验
4. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
5. Patient Self-report on an MDHAQ (Multidimensional Health Assessment Questionnaire) Appears to Provide Superior Documentation of Possible Adverse Events of Methotrexate than a Physician Note in an Electronic Medical Record [D] . Abu Mehsen, Sara. 2020

机译：患者在MDHAQ（多维健康评估问卷）上的自我报告似乎提供卓越的甲氨蝶呤可能不良事件，而不是电子病历中的医生注意事项
6. Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial [O] . Akira Ooki, Satoshi Morita, Akihito Tsuji, 2020

机译：患者和医生报告的症状不良事件结果的分歧是用一线加妥昔单抗和化疗治疗不可切种的转移性结直肠癌的患者的预后差：II期嘎嘎试验的结果
7. A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial [O] . Shigeyoshi Iwamoto, Akira Ooki, Satoshi Morita, 2018

机译：一项潜在的第二阶段研究，审查KRA野生型不可切入转移性结直肠癌患者第一线化疗与甲磺替昔单抗的生活质量和不良事件之间的关系

Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial

著录项

相似文献

相关主题

期刊订阅